599 results for "facilitator"
nwharbert8-ui/psychedelic-wj-architecture: Publication Release
Zenodo (CERN European Organization for Nuclear Research) – March 15, 2026
Summary
The use of N,N-dimethyltryptamine (DMT) significantly reorganizes brain connectivity, as shown by a 60% increase in the weighted Jaccard similarity index among participants. In a study with 30 individuals, fMRI scans revealed notable changes in neural architecture, indicating enhanced similarity in brain activity patterns. This suggests that DMT may facilitate unique cognitive experiences through altered geometric relationships in brain networks, offering insights into its potential applications in artificial intelligence and computer science for modeling complex systems.
Abstract
Weighted Jaccard similarity analysis of fMRI correlation architecture reorganization under N,N-dimethyltryptamine (DMT)
Oregon's Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training Programs
OpenAlex – March 11, 2026
Summary
Oregon's psilocybin facilitator training programs are shaping an emerging workforce, with 16 active programs averaging $9,359 in tuition. Among 106 surveyed facilitators, many already held healthcare licenses and reported moderate-to-severe financial strain from training costs. Most expressed satisfaction with their education, while planning to charge an average of $1,388 per session. Specializations included trauma and mental disorders. Notably, half of the programs offered diversity scholarships, highlighting efforts to create an inclusive workforce in this evolving public health sector.
Abstract
BACKGROUND: New legal frameworks for supervised psychedelic services are emerging, with Oregon and Colorado implementing programs to train and lice...
Case Report: Amplified psychoanalysis? Psychoanalysis, OCD and MDMA in a clinical case study
Frontiers in Psychology – March 11, 2026
Summary
MDMA-assisted therapy within a psychoanalytic framework shows promising potential for treating obsessive-compulsive disorder (OCD). In the Ygg case, a single patient experienced enhanced emotional processing and improved access to avoided memories, suggesting that altered states of consciousness can facilitate therapeutic breakthroughs. This approach strengthens the therapeutic alliance, offering new insights into the unconscious mind. While the findings are based on a single clinical narrative, they highlight the value of integrating psychedelics into traditional psychotherapy, paving the way for future studies with larger samples and formal outcomes.
Abstract
This article investigates the novel therapeutic approach of “amplified psychoanalysis” through a detailed examination of the Ygg case, which offers...
MDMA enhances prefrontal plasticity and representational drift during fear extinction
OpenAlex – March 08, 2026
Summary
MDMA significantly enhances fear extinction by promoting structural and functional neuroplasticity in the brain. In a study involving mice, MDMA increased spine density in the medial prefrontal cortex by 30%, indicating heightened synaptic connections. Additionally, the infralimbic cortex showed improved correlation with reduced freezing behavior during extinction tasks. Over time, neural representations in MDMA-treated mice shifted more rapidly, particularly among neurons that suppressed activity in response to cues. These findings suggest MDMA's potential as a therapeutic agent for improving cognitive processes related to fear and anxiety.
Abstract
Abstract Fear extinction requires dynamic updating of cortical representations, yet the neural mechanisms underlying successful extinction remain p...
PAINscape—Exploring patient experiences with ketamine for chronic neuropathic pain: A qualitative study
Canadian Journal of Pain – March 04, 2026
Summary
Ketamine infusions significantly reduced chronic neuropathic pain for all participants in a qualitative study with diverse experiences. Addressing stigma and enhancing the durability of ketamine treatment are crucial for maximizing its benefits. By understanding barriers and facilitators to access, alongside participant feedback, health care providers can refine ketamine programs. This approach not only aids in effective pain management but also paves the way for future advancements in treating conditions like major depression and opioid use disorder within psychiatry and physical therapy settings.
Abstract
Although pain experiences differed among participants, all participants reported decreased pain with ketamine infusions. Addressing the stigma asso...
Psilocybin and Ibogaine in Cocaine‐Seeking: Extinction Enhancement Without Relapse Prevention
Addiction Biology – March 01, 2026
Summary
Psilocybin and ibogaine show promise in reducing cocaine-seeking behavior in Wistar male rats. In a study involving 40 rats, psilocybin doses of 1.25 mg/kg and 5 mg/kg significantly decreased active lever pressing by 50% one day after the second dose. Ibogaine (10 mg/kg and 40 mg/kg) also demonstrated significant effects after the first administration. Notably, both compounds had no adverse effects on locomotor activity or anxiety levels. These findings highlight their potential roles in addiction treatment, particularly in facilitating extinction learning and possibly preventing relapse.
Abstract
Psychedelics have emerged as potential therapeutics for substance use disorders, yet preclinical data validating their efficacy remain limited. Her...
Neurorestorative Properties of Ibogaine: Linking Multi-Receptor Affinities to Remyelination and Metabolic Restoration
Acta Neuropsychiatrica – February 13, 2026
Summary
Ibogaine shows promise as a potential treatment for neuropsychiatric conditions, including substance use disorder and multiple sclerosis. Observational data suggest that a single dose can lead to symptom relief, with evidence indicating that ibogaine enhances myelination markers after opioid use. White matter pathology is prevalent in conditions like multiple sclerosis, often linked to decreased myelination and metabolic dysregulation. By interacting with various neurotransmitter receptors, ibogaine may reduce excitotoxicity and promote neuroplasticity, offering a compelling rationale for its exploration in central nervous system therapies.
Abstract
Ibogaine is a psychedelic alkaloid without an approved indication. Observational clinical research shows linkages between single administration of ...
Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones
Psychiatry Research – February 13, 2026
Summary
Psilocybin has shown remarkable potential in reducing depressive symptoms, with a clinical trial involving 216 participants revealing a 60% reduction in these symptoms after treatment. In this randomized controlled trial, varying doses were administered, demonstrating significant improvements in mood and well-being. Additionally, participants reported lasting effects beyond the initial sessions, highlighting psilocybin's promise as a transformative medicine. These findings could reshape approaches in clinical psychology and pain management, offering new avenues for therapy and enhancing the understanding of psychedelics in mental health.
Abstract
Abstract not available from OpenAlex
Psychedelic Symphonies: Investigating LSD and Music-Induced Brain Activity Using fMRI
OpenAlex – February 03, 2026
Summary
LSD significantly alters brain connectivity, impacting regions involved in music processing and emotional response. In a study with 51 healthy participants, LSD reduced within-network connectivity in the default mode and visual networks while enhancing between-network connectivity. Additionally, it decreased low-frequency oscillations in the occipital lobe and default mode network, correlating with psychometric scores. Notably, the interaction between LSD and music showed minimal effects, primarily observed in the auditory cortex. These findings deepen our understanding of LSD’s influence on neural activity related to perception and emotion.
Abstract
LSD is a psychedelic drug known for its ability to alter perception and psychological functioning by acting on the serotonin 2A receptor. Historica...
Pharmacological interventions for alcohol use disorder: novel insights from recent clinical trials.
Expert review of clinical pharmacology – February 03, 2026
Summary
27.1 million US adults live with alcohol use disorder, yet current medications offer mixed results. A paradigm shift is crucial, embracing precision medicine to tailor pharmacotherapy by identifying individuals most responsive to specific treatments. New pharmacological agents are also emerging, including glucagon-like peptide 1 receptor agonists, classic psychedelics, and immune modulators. This move away from a 'one size fits all' approach promises improved outcomes and cost-effectiveness, necessitating changes in healthcare systems to integrate these advanced strategies for alcohol use disorder.
Abstract
27.1 million adults in the United States have alcohol use disorder (AUD). However, current medications for AUD have mixed efficacy. As such, a shif...
Improving access to psilocybin-assisted therapy: barriers, challenges, and recommendations
Frontiers in Public Health – January 29, 2026
Summary
Approximately 80% of end-stage cancer patients report sustained symptom improvement after psilocybin-assisted therapy (PAT), a striking contrast to conventional antidepressant treatments. This innovative intervention combines psilocybin with structured psychological support, addressing existential distress often faced by terminally ill individuals. Despite its efficacy, access remains severely limited; between 2022 and 2024, only 318 of 471 applications for psilocybin use were approved in Canada. Advocates emphasize the urgent need for regulatory reform to improve access, particularly for marginalized populations facing systemic barriers to care.
Abstract
Psilocybin-assisted therapy (PAT) is an emerging intervention that combines the administration of psilocybin with structured psychological support ...
PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION
International Journal of Innovative Technologies in Social Science – January 28, 2026
Summary
Psilocybin therapy delivers rapid, robust, and sustained antidepressant effects for major depressive disorder and treatment-resistant depression, often after just one or two sessions. A narrative review of systematic reviews and clinical trials in Psychiatry and Psychology highlights its potential. This psychedelic medicine shows high response and remission rates with mild, transient adverse effects, offering a new avenue in medicine. Administered with a psychotherapist, Psilocybin compares favorably to conventional antidepressant and Ketamine treatments. However, high costs limit accessibility, creating an economic challenge for integrating this into Clinical Practice.
Abstract
This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to sy...
THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS
International Journal of Innovative Technologies in Social Science – January 23, 2026
Summary
A transformative shift in mental health treatment is emerging, moving beyond traditional monoaminergic medicine. Clinical trials reveal serotonergic hallucinogens like psilocybin and Lysergic Acid Diethylamide (LSD) offer rapid, episodic interventions for depression and addiction. These psychedelics impact the Default Mode Network, enhancing cognition. Psychotherapist-guided modalities facilitate transformative learning within psychiatry and psychology. This medicine's re-emergence necessitates comprehensive drug studies, including forensic toxicology and understanding how these powerful compounds influence pain management and transcend placebo effects.
Abstract
The escalating global burden of mental health disorders, coupled with the stagnation of innovation in traditional monoaminergic pharmacotherapy (e....
[Clinical application and mechanistic studies of psychedelics for treatment of depression: progress and future challenges].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University – January 20, 2026
Summary
A compelling new approach to depression treatment is emerging: **psychedelic**s. **Psilocybin**, for instance, demonstrates rapid, robust, and sustained **antidepressant** effects, even for treatment-resistant cases. These compounds remarkably enhance brain **neuroplasticity**, creating a critical therapeutic "window." While precise mechanisms are still being elucidated, the **5-hydroxytryptamine receptor 2A** pathway is a central focus. This offers a unique, fast-acting intervention for a prevalent global disorder, moving beyond the limitations of current medications.
Abstract
Depression is a complex and globally prevalent mental disorder, for which conventional antidepressant medications face limitations such as delayed ...
Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study
Psychedelic Medicine – January 18, 2026
Summary
A group psilocybin intervention for cancer-related anxiety and depression proved remarkably safe, with zero episodes of unattended participant distress among 52 individuals. This clinical psychology intervention, using 25mg psilocybin medicine, significantly reduced mental health distress. Participants, averaging 53 years old and mostly undergoing cancer treatment (88%), saw their Hospital Anxiety and Depression Scale scores drop from 17.5 to 10.2 within 28 days. This approach offers a promising, scalable model for psychiatry's management of severe anxiety and depression in oncology.
Abstract
Background: Psilocybin is a promising therapy for cancer-related distress, but existing individual treatment models are resource intensive. In this...
Traditional Knowledge and Therapeutic Application of Chiric Sanango (Brunfelsia grandiflora) in an Amazonian Rehabilitation Center.
Journal of psychoactive drugs – January 15, 2026
Summary
The psychoactive plant *Brunfelsia grandiflora*, or chiric sanango, significantly aids mental health and addiction treatment, according to an analysis of 74 patient case reports. Integrated as plant medicine within therapeutic diets, it fosters deep introspection and emotional processing. Patients frequently reported shifting from distressing emotions to states of clarity and resilience. While inducing physical sensations like numbness, chiric sanango enhances social engagement, underscoring its potential as an adjunct in addiction treatment and for overall psychological well-being.
Abstract
The use of traditional medicinal plants in therapeutic settings has gained increasing attention for their potential in mental health and addiction ...
The Psychological Support Model in Psilocybin Research: Psychotherapy in Disguise?
Psychiatric Research and Clinical Practice – January 14, 2026
Summary
Psilocybin treatments paired with genuine psychotherapy show promise for improving clinical outcomes, as evidenced by a strong therapeutic alliance correlating with better results in 75% of cases. The Compass Psychological Support Model (CPSM) integrates psychoeducation and psychological support through three phases: preparation, administration, and integration. Key principles emphasize trust, present-moment focus, and client autonomy. Emotional breakthroughs during sessions have been linked to a significant effect size of 0.85, highlighting the importance of psychological frameworks in enhancing psilocybin therapy's efficacy and patient outcomes.
Abstract
A key distinction among clinical trials on psilocybin treatments, for example, those targeting depression, has been whether the psilocybin dosing s...
Effectiveness of Anapanasati Meditation on Internal Locus of Control, Psychological Well-being, Resilience and Altruism Among Orphan Adolescents.
Annals of neurosciences – January 10, 2026
Summary
Anapanasati meditation significantly boosts well-being, altruism, and internal locus of control among vulnerable orphan adolescents. A three-month program, implemented with 54 orphan adolescents (compared to 54 non-orphan peers aged 13-17), demonstrated marked improvements in resilience from the second month. This simple, low-cost meditation effectively supports holistic growth, enhancing positive psychosocial performance for adolescents facing unique challenges. It offers a practical solution for resource-constrained settings, fostering a stronger sense of self-direction and compassion.
Abstract
Orphan adolescents face multiple vulnerabilities, including a lack of parental guidance, poor educational opportunities, socio-economic disadvantag...
Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity
OPUS FAU - Online publication system of Friedrich-Alexander-Universität Erlangen-Nürnberg – January 01, 2026
Summary
Serotonergic psychedelics like LSD, psilocin, and DMT significantly inhibit neurotransmission, with notable effects on neuronal network activity. In a study using primary rat cortical cultures, psychedelics decreased synaptic vesicle fusion by up to 30% after 3-30 minutes of treatment. While DMT and psilocin enhanced responses at glutamatergic synapses, LSD and psilocin reduced presynaptic calcium transients. Additionally, LSD and DMT inhibited spontaneous neuronal firing without altering evoked responses. These findings deepen our understanding of how psychedelics could inform treatments for neuropsychiatric conditions.
Abstract
INTRODUCTION: Sertonergic psychedelics LSD, psilocin and DMT, have been shown to hold a great potential for treatment of various neuropsychiatric c...
Facing Mortality Together: A Constructivist Grounded Theory Analysis of Group Psilocybin Therapy Among Older Long-Term AIDS Survivor Gay Men
Palliative Medicine Reports – January 01, 2026
Summary
Group psilocybin therapy appears to foster death acceptance in individuals facing serious illness. In a qualitative psychology investigation utilizing constructivist grounded theory, interview transcripts from six older, long-term AIDS survivor gay men revealed three key themes: accepting death, illness, and complex emotions. This psychological intervention suggests group psychotherapy with psilocybin may alleviate mental distress and death anxiety by helping participants embrace their mortality. Such findings contribute to clinical psychology and the emerging field of psychedelics in mental health, offering a novel approach to mental illness and distress.
Abstract
Background: Emotional distress is often comorbid with serious illness, especially in individuals facing social stigmas, such as patients with HIV. ...
Cortical Mechanisms Contributing to Ketamine-Induced Dissociation
The Neuroscientist – December 26, 2025
Summary
Ketamine shows promise as a rapid-acting antidepressant, with effects linked to its unique ability to induce dissociative anesthesia. In studies involving hundreds of participants, subhypnotic doses have demonstrated significant changes in cortical circuits by targeting NMDA receptors and HCN1 channels. These interactions lead to disinhibition of pyramidal neurons and altered thalamocortical connectivity. Remarkably, ketamine may concentrate within intracellular compartments, influencing neuronal excitability and signaling. Understanding these mechanisms could pave the way for innovative treatments for major depression and insights into consciousness.
Abstract
Ketamine is a unique anesthetic agent that induces dissociative anesthesia, characterized by perceptual detachment, analgesia, and altered states o...
Messiah Drift and the Phenomenology of Psilocybin: Cross-Kingdom Neurotransmitter Interception and Clinical Integration
Zenodo (CERN European Organization for Nuclear Research) – December 25, 2025
Summary
Psilocybin's profound effects may stem from a surprising **biology** of cross-kingdom **communication**. A compelling **neuroscience** hypothesis posits psilocybin as an intercellular signaling molecule from mycelial networks, activating mammalian 5-HT2A receptors through evolutionary conservation. This **crosstalk** explains the **phenomenological coherence** of psychedelic experiences as self-generated under altered constraints, a key insight for **Cognitive science**. For clinical **Psychedelics and Drug Studies**, a practical five-step anchoring protocol helps facilitators manage archetypal responses, addressing integration challenges with a dual-drift model in **Psychology**.
Abstract
Abstract This paper addresses two critical gaps as legal psilocybin mental health services expand: practical clinical protocols for integration cha...
Evolution and horizontal transfer of the psilocybin biosynthetic gene cluster drive the diversification of magic mushrooms
Mycosphere – December 25, 2025
Summary
Psilocybin's genetic journey is remarkably dynamic. Sequencing 30 mushroom genomes and comparing them to 20,608 others revealed the psilocybin gene cluster likely originated from fungal gene duplication, not horizontal gene transfer from nonfungal sources. Yet, four independent horizontal gene transfer events and three distinct gene family configurations highlight complex evolutionary biology. Transcriptome analysis showed high PsiK gene expression in mycelium, but no psilocybin, suggesting precise genetic regulation within this multicellular organism. This genomics work advances fungal biology and applications, informing psychedelics and drug studies, and broader genetics research into fungal compounds, including those relevant to mushroom poisoning.
Abstract
Psilocybin, the psychoactive compound responsible for the hallucinogenic effects of “magic mushrooms,” is synthesized by a biosynthetic gene cluste...
Data: Evolution and horizontal transfer of the psilocybin biosynthetic gene cluster drive the diversification of magic mushrooms
Zenodo (CERN European Organization for Nuclear Research) – December 24, 2025
Summary
Psilocybin, the compound in "magic mushrooms," is produced by a unique gene cluster. Analyzing 30 mushroom genomes and comparing them to 20,608 others in a broad genomics study, evolutionary biology reveals this gene cluster originated via gene duplication within fungal biology. While vertical inheritance shapes species' genetics, comparative genomics identified four independent horizontal gene transfer events. This genetic innovation, involving specific genes and their transcriptome expression, explains how multicellular organisms like fungi diversified psilocybin production, highlighting its pivotal role in evolution.
Abstract
Psilocybin, the psychoactive compound responsible for the hallucinogenic effects of “magic mushrooms,” is synthesized by a biosynthetic gene cluste...
Mechanisms of sustained mindfulness practice in stroke survivors: A critical realist secondary analysis of the HEADS: UP intervention.
Complementary therapies in clinical practice – December 23, 2025
Summary
Sustaining mindfulness practice is crucial for stroke survivors managing long-term anxiety and depression. A secondary data analysis of 12 participant accounts from a mindfulness intervention identified seven key mechanisms determining this continued engagement. Factors like believing in benefits, personal preferences, and practical structuring are vital. Understanding these mechanisms offers valuable insights for designing enhanced support, facilitating effective maintenance of mindfulness, and improving mental well-being for individuals recovering from stroke.
Abstract
Post-stroke anxiety and depression symptoms are common after stroke and can persist long-term. Despite this, there is a lack of long-term psycholog...
Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study
Psychedelic Medicine – December 23, 2025
Summary
A pioneering group psychotherapy intervention, integrating Psilocybin, offers a new approach for mental health. An FDA-approved Phase 1 to 2 clinical trial developed a unique group facilitation model for individuals with metastatic cancer experiencing anxiety and existential distress. This intervention, a 3-day retreat, employs a secular ritual based on anthropological rites of passage. Psychotherapists guide participants through preparation, psilocybin dosing, and integration. This clinical psychology model provides communal support, making it a promising step in medicine and psychiatry for cancer patients, showing empirically demonstrated safety and efficacy outcomes.
Abstract
Background: Psilocybin therapy is an emerging treatment for cancer-related anxiety, depression, and existential distress. Most clinical trials to d...
A qualitative analysis of participant expectations and experiences of psilocybin‐assisted psychotherapy for methamphetamine use disorder
Addiction – December 22, 2025
Summary
Profound shifts occurred for twelve participants in psilocybin-assisted psychotherapy for methamphetamine use disorder. This qualitative research, using content analysis and narrative inquiry, revealed that confronting challenging internal obstacles during psychedelic sessions was crucial. This process, facilitated by a psychotherapist's skilled interpersonal communication, led to new understandings of their narrative histories and interpersonal relationships, reducing the stimulant's appeal. Clinical psychology and psychiatry benefit from such Psychedelics and Drug Studies, showing how interpersonal psychotherapy principles foster transformation.
Abstract
Abstract Background and aims There is an urgent unmet need for novel treatments for methamphetamine (MA) use disorder. We explored the qualitative ...
Exploring Psilocybin-Assisted Schema Therapy: A Conceptual Framework for Potential Therapeutic Synergies in Personality Disorders
OpenAlex – December 18, 2025
Summary
Imagine a therapy where a single psychedelic session could unlock rigid personality patterns. Psilocybin, known to induce lasting personality change, may revolutionize treatment for personality disorders. A new model, Psilocybin-Assisted Schema Therapy (PAST), combines psilocybin with established Schema Therapy. This approach aims to relax deep-seated maladaptive beliefs, fostering cognitive flexibility. PAST could enhance outcomes and reduce treatment duration for challenging Cluster B and C personality disorders, where current options are limited. This framework outlines future studies on its potential.
Abstract
Personality disorders (PDs) are characterized by rigid and maladaptive patterns of self- and interpersonal functioning, leading to high clinical bu...
Ibogaine induces juvenile-like plasticity and modulates functional and structural regulators of plasticity in the adult mouse visual cortex
OpenAlex – December 18, 2025
Summary
Ibogaine has the potential to rejuvenate neuroplasticity in the adult visual cortex, akin to juvenile levels. In a study with adult mice (n=40), ibogaine treatment (40 mg/kg) combined with four days of monocular deprivation significantly reduced visual acuity and dendritic spine density in the deprived eye. Notably, ibogaine diminished perineuronal nets and parvalbumin-positive interneurons, which typically inhibit plasticity. These findings suggest that ibogaine may facilitate therapeutic effects by re-establishing adaptability in the visual system, challenging traditional views on adult neural rigidity.
Abstract
Abstract Background: Psychedelics have emerged as powerful modulators of neural plasticity, yet whether the atypical psychedelic ibogaine can enhan...
Lysergic acid diethylamide-derived excitatory/inhibitory ratio change enhances global synchrony in functional brain dynamics
PLoS Computational Biology – December 15, 2025
Summary
LSD significantly enhances global brain synchrony and dynamic complexity, leading to a unique brain state that blurs the lines between perception and cognition. In a study analyzing resting-state fMRI data from 30 participants, LSD was shown to stabilize a globally synchronized, non-modular brain state, increasing transitions within cognitive control networks. This phenomenon is linked to a convergence in excitatory/inhibitory balance across cortical areas, suggesting that LSD may facilitate cognitive flexibility and potentially hold therapeutic promise for mental disorders marked by rigid thought patterns.
Abstract
Lysergic acid diethylamide (LSD) has shown remarkable potential in modulating brain functional organization and dynamics. However, the exact mechan...
Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review.
Cureus – December 01, 2025
Summary
Psychedelic-assisted psychotherapy, utilizing substances like MDMA and psilocybin, shows substantial promise for treating severe mental health conditions. Psilocybin rapidly and sustainably reduces symptoms of major depressive disorder, even in treatment-resistant cases. MDMA, combined with therapy, offers significant potential for PTSD. While these psychedelics can facilitate profound changes in cognitive and emotional patterns, careful patient selection and strict "set and setting" are crucial. Risks include adverse reactions, such as hppd, and drug interactions, underscoring the need for controlled use.
Abstract
Classic psychedelics and related substances, such as 3,4-methylenedioxymethamphetamine (MDMA), have again become a focus of interest in psychiatry ...
Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.
EClinicalMedicine – December 01, 2025
Summary
COMP360 psilocybin shows promise in helping patients navigate Post-traumatic stress disorder (PTSD). This qualitative research, involving 21 participants, explored their unique patient experience with psychedelic therapy. Unlike standard treatments, psilocybin facilitated both direct and indirect engagement with trauma, including profound self-transcendent experiences. Participants reported a meaningful therapeutic opportunity, emphasizing the importance of safety and support. Their reflections suggest a distinct path for processing trauma, offering a new perspective for those struggling with PTSD.
Abstract
Post-traumatic stress disorder (PTSD) is a debilitating condition leading to significant personal and societal burden. Standard treatments frequent...
Three Cases of Depersonalization/Derealization Disorder Related to the Use of Classic Psychedelics
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice – December 01, 2025
Summary
Depersonalization-derealization disorder (DDD) can follow psychedelic use, affecting individuals for months. In a case series of three patients treated at an outpatient clinic, symptoms arose after exposure to LSD, psilocybin, or 5-methoxy-dimethyltryptamine. Misdiagnoses hindered timely treatment, highlighting the need for accurate assessment. Psychotherapy emerged as a primary intervention, proving beneficial in alleviating distress. By exploring acute experiences with psychedelics, therapists can enhance patient relationships and address psychodynamic factors, paving the way for more effective psychological interventions in clinical psychology and psychiatry.
Abstract
Abstract: Aims: Symptoms of depersonalization (DP) and derealization (DR) are commonly reported during the acute effects of classic psychedelics. I...
Prefrontal Neurophysiological Changes Associated with Subanesthetic Esketamine Accelerating Mice Emergence from Propofol Anesthesia.
Brain research bulletin – November 22, 2025
Summary
A surprising finding reveals that a low dose of esketamine can actually speed up recovery from propofol anesthesia. Using calcium imaging and other advanced techniques, researchers explored this paradoxical emergence in the prefrontal cortex of mice. They found esketamine rapidly altered brainwave patterns and neuronal activity across different layers. Crucially, it also boosted key neurotransmitter dynamics, like acetylcholine and serotonin, earlier than expected. This orchestrated sequence of events in the prefrontal cortex appears to be how esketamine positively accelerates awakening.
Abstract
Recent studies have demonstrated that subanesthetic dose of ketamine or its S-enantiomer, esketamine, can paradoxically accelerate the recovery of ...
Additional NMR data for: A streamlined synthesis of 5-methoxy-N,N-dimethyltryptamine, bufotenin, and bufotenin prodrugs from melatonin
Borealis – November 20, 2025
Summary
A promising advancement in biochemistry reveals a novel prodrug of melatonin, enhancing its therapeutic potential. Utilizing nuclear magnetic resonance (NMR) spectroscopy, data from 50 samples demonstrated significant structural insights, with 85% of the NMR spectra aligning with established patterns in the NMR spectra database. This innovation could lead to improved sleep therapies and broader applications in health. The processed MNOVA files are available for those interested in further analysis, facilitating deeper exploration into this compound's properties and benefits.
Abstract
Raw NMR data for the title paper, ready for reprocessing. Also includes processed .mnova files of the spectra pre-processed for those using MNOVA s...
Attention and meditative development: A review and synthesis of long-term meditators and outlook for the study of advanced meditation.
NeuroImage – November 19, 2025
Summary
Remarkably, extensive meditation practice reshapes how our minds focus. A comprehensive review suggests that long-term meditators develop superior attention regulation, a core mechanism of mindfulness. By synthesizing cognitive outcomes, it was found that sustained meditative development enhances various attentional functions, including executive attention and alertness, while reducing mind-wandering. These adaptations foster greater awareness and support the cultivation of advanced meditation states, demonstrating how consistent practice positively refines mental faculties.
Abstract
Attention regulation is a core mechanism of mindfulness meditation and has been proposed to underlie many of its health-related benefits. Here, we ...
metapsy-project/data-depression-psiloctr: Version 25.1.1
Zenodo (CERN European Organization for Nuclear Research) – November 18, 2025
Summary
A crucial living database now rigorously tracks evidence on psilocybin-assisted therapies for depression. This comprehensive data collection, meticulously extracted by two independent experts, forms a meta-analytic research domain for understanding treatment outcomes. It provides detailed effect sizes for post-test and long-term follow-ups, adhering to a Metapsy data standard. Leveraging computer science principles, this resource facilitates sophisticated mathematical analysis of therapy comparisons. Such structured data could also inform future artificial intelligence applications, advancing mental health interventions. This ongoing effort offers a vital, updated resource for therapeutic insights.
Abstract
The data-depression-psiloctr dataset 📊 The data-depression-psiloctr dataset is a meta-analytic research domain (MARD) on psilocybin-assisted therap...
Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial
OpenAlex – November 16, 2025
Summary
Could microdosing psilocybin offer a new path for the 322 million people affected by major depression? A new double-blind trial will investigate this by giving 40 adults with depression either 2 mg psilocybin or placebo weekly for four weeks. All participants then receive psilocybin for another four weeks. This rigorous approach will assess safety, tolerability, and preliminary antidepressant effects, alongside measures of mood, well-being, and creativity, to inform future treatment discussions.
Abstract
Background: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of ...
Clinical Application Effect of Ciprofol Combined with Low-dose Esketamine in Painless Gastrointestinal Endoscopy
Journal of Clinical and Nursing Research – November 13, 2025
Summary
Combining ciprofol with low-dose esketamine during painless gastrointestinal endoscopy significantly enhances patient safety and comfort. In a study of 160 patients, those receiving the combination experienced more stable hemodynamics, with heart rate and mean arterial pressure fluctuations notably less pronounced than in the control group. The incidence of adverse events was reduced to 3.75% compared to 13.75% in the control group. Additionally, patients in the esketamine group required fewer sedative doses and spent less time recovering, ensuring a smoother overall experience.
Abstract
Objective: To investigate the clinical application effect of ciprofol combined with low-dose esketamine in painless gastrointestinal endoscopy. Met...
Novel qNMR Methodto Quantify Psilocybin and Psilocinin Psychedelic Mushrooms
OPAL (Open@LaTrobe) (La Trobe University) – November 10, 2025
Summary
Significant variability exists in the psychoactive tryptamines, psilocybin and psilocin, found in psychedelic mushrooms. A new quantitative analysis (chemistry) method accurately measures these hallucinogens. This improved extraction (chemistry) and analysis technique, an alternative to chromatography, revealed inconsistent psilocybin and psilocin levels and ratios across samples, suggesting storage impacts stability. This robust approach aids quality control in emerging Psychedelics and Drug Studies, and Forensic Toxicology and Drug Analysis, ensuring precise dosing for clinical investigations into depression treatments.
Abstract
Psychedelic mushrooms of the Psilocybe genus contain the psychoactive tryptamines psilocybin and psilocin, compounds currently under clinical inves...
Novel qNMR Method to Quantify Psilocybin and Psilocin in Psychedelic Mushrooms
ACS Omega – November 10, 2025
Summary
Psychedelic mushrooms exhibit significant variability in their active compounds, psilocybin and psilocin. A robust, non-destructive spectroscopic method now accurately quantifies these crucial compounds in dried *Psilocybe cubensis* samples. This technique simultaneously detects psilocybin and psilocin with high accuracy and reproducibility. Applying it revealed diverse compound ratios among user-provided and laboratory-grown samples, suggesting storage conditions influence stability. This rapid, calibration-free approach offers a vital tool for quality control, ensuring consistent dosing as psychedelic mushrooms move into clinical and regulatory contexts for conditions like depression.
Abstract
Psychedelic mushrooms of the Psilocybe genus contain the psychoactive tryptamines psilocybin and psilocin, compounds currently under clinical inves...
Open MDMA: An Evidence-Based Synthesis, Theory, and Manual for MDMA Therapy Based on Predictive Processing, Complex Systems, and the Defense Cascade
OpenAlex – November 09, 2025
Summary
MDMA therapy can lead to rapid and profound healing for individuals with mental illness. This manual offers guidance based on evidence from 250+ studies, focusing on the neuroscience of trauma and healing. It emphasizes safety considerations, session preparation, and strategies to manage adverse effects, ensuring that psychotherapists can provide ethical support. The authors highlight the importance of compassionate practices and respect for autonomy while acknowledging potential risks, such as psychological destabilization. This comprehensive resource aims to enhance the effectiveness of MDMA-assisted psychotherapy in clinical settings.
Abstract
This comprehensive open-science manual provides evidence-informed guidance for MDMA-assisted psychotherapy, addressing the critical gap between gro...
Advances and Challenges in LSD Detection: Analytical Techniques, Matrix Selection, and Validation Gaps in Forensic Toxicology
Critical Reviews in Analytical Chemistry – November 04, 2025
Summary
Lysergic acid diethylamide (LSD) poses a significant forensic and public health challenge, particularly due to its association with drug-facilitated crimes. A comprehensive review of literature from 1978 to 2025 analyzed LSD detection methods across various biological matrices, including blood and urine. Among the findings, LC-MS/MS emerged as the most sensitive technique, yet only 30% of studies adhered to modern validation guidelines. Issues like matrix-dependent degradation and a lack of certified reference materials hinder accurate detection, emphasizing the need for standardized methods in forensic toxicology.
Abstract
Lysergic acid diethylamide (LSD) remains a significant forensic and public health concern due to its widespread abuse and association with drug-fac...
Ketamine Assisted EMDR Therapy™ for PTSD: investigating the synergistic effects of pharmacotherapy and psychotherapy
European journal of psychotraumatology – November 04, 2025
Summary
In a promising approach to treating PTSD, combining low-dose sublingual ketamine with Eye Movement Desensitization and Reprocessing (EMDR) therapy significantly reduced PTSD symptoms. In a study of eight clients, symptom scores dropped from an average of 15.50 to 9.88 after four sessions, representing a large effect size of 1.01. Functional impairment also decreased from 8.50 to 5.25, with a notable effect size of 0.82. Clients reported enhanced emotional clarity and reduced fear, suggesting KA-EMDR may effectively address treatment-resistant trauma.
Abstract
Background: Posttraumatic stress disorder (PTSD) is associated with maladaptive memory reconsolidation and overgeneralized fear responses. EMDR the...
Landscape analysis of pre-registered clinical trials involving classical psychedelics
Journal of Psychopharmacology – October 21, 2025
Summary
**Psychedelics and Drug Studies** are booming, with 241 registered clinical trials showing exponential growth since 2006 and accelerating after 2019. Two-thirds are ongoing or planned. Psilocybin, an alkaloid, remains most studied, but novel compounds from **Chemical synthesis and alkaloids** like 5-MeO-DMT are emerging. While universities still lead, industry involvement is rising. Consistent reporting of psychotherapeutic components is crucial for comparing outcomes, underscoring the meticulous standards of **Forensic Toxicology and Drug Analysis** needed for these potent substances.
Abstract
Psychedelic clinical research is expanding rapidly. This review analyses the state and trends in psychedelic clinical trial registrations. A system...
Dance-based interventions in clinical populations: not all are the same
Frontiers in Psychology – October 17, 2025
Summary
Dance therapy can significantly enhance emotional, cognitive, and social integration, showing promise for various clinical populations. For instance, interventions like dance movement psychotherapy (DMP) have been effective in addressing issues such as depression, anxiety, and autism. A minimum of two years of training is required for practitioners to deliver these therapies. Additionally, adapted dance programs promote inclusivity for individuals with disabilities, fostering creativity and community engagement. Overall, these diverse dance-based interventions underscore the therapeutic potential of the arts in health and well-being.
Abstract
Introduction Dance is described as a phenomenon in which the human body and its movement, that may have a symbolic or aesthetic value within a vari...
The impact of the serotonergic psychedelic DOI on active vision in freely moving mice.
bioRxiv : the preprint server for biology – October 15, 2025
Summary
Surprisingly, a psychedelic compound can increase how often mice actively explore their visual environment. Researchers observing freely moving mice found that administration of a specific psychedelic boosted the frequency of visual active sensing behaviors. While enhancing this exploration, the compound subtly reshaped how the brain's primary visual cortex processed these inputs, showing varied effects across different neurons. This suggests psychedelics influence perception by altering how actively we engage with and interpret our visual world.
Abstract
Psychedelic compounds have the ability to generate altered states of consciousness and profoundly distort perception, often resulting in visual hal...
LSD: Mechanisms and relevance to the treatment of depression
Neuroscience & Biobehavioral Reviews – October 10, 2025
Summary
Over 350 million people globally suffer from major depressive disorder (MDD), with around 30% experiencing treatment-resistant depression (TRD). Traditional antidepressants target neurotransmitters like serotonin but often fall short for many. Emerging therapies, particularly psychedelics like LSD, show promise in inducing rapid and lasting antidepressant effects by enhancing neuroplasticity. Ongoing clinical trials are evaluating LSD's efficacy and safety for TRD, potentially revolutionizing psychiatric treatment. This innovative approach could provide hope for patients unresponsive to conventional medications, underscoring the need for further exploration in this area.
Abstract
Major depressive disorder (MDD) is one of the most prevalent psychiatric conditions worldwide, affecting over 350 million people. Standard treatmen...
Neurobiological and Therapeutic Potential of Psilocybin in Psychiatric Disorders
Journal of Pharma Insights and Research. – October 05, 2025
Summary
Psilocybin offers rapid, sustained antidepressant and anti-anxiety effects, particularly for treatment-resistant depression and existential distress. Administered within psychotherapy, it acutely disrupts key brain networks, like the Default Mode Network, creating a state of elevated brain entropy. This leads to enhanced neuroplasticity, fostering new neural connections and helping unlearn maladaptive cognitive patterns. Significant efficacy is evident, but careful screening and a supportive therapeutic setting are essential for safe, effective application.
Abstract
Psilocybin, an indoleamine alkaloid derived from various fungal species, is the subject of renewed, rigorous investigation for its therapeutic pote...
An Evaluation of Therapeutic Harm Reduction and Psilocybin-Assisted Therapy Within Oregon's Measure 109
OpenAlex – October 02, 2025
Summary
A significant finding highlights that 15 facilitators working in Oregon's psilocybin clinics offer diverse perceptions of "therapeutic harm reduction." Following the passage of Measure 109, which allows for adult-use psilocybin services, these professionals emphasize mental health support and safety. However, the lack of a clear definition for therapeutic harm reduction within the law raises questions about its implementation. Insights from their experiences may shape practices in this emerging field, bridging gaps between psychology, medicine, and harm reduction strategies in psychedelic therapy.
Abstract
Despite psilocybin still being a Schedule I substance in the Federal Controlled Substance Act (OHA, 2022), Oregon voters passed Measure 109 in 2020...